© 1999 American Heart Association, Inc.
Original Contributions |
Single and Combined Prothrombotic Factors in Patients With Idiopathic Venous Thromboembolism
Prevalence and Risk Assessment
From the Institute of Thrombosis and Hemostasis, Department of Hematology, Sheba Medical Center, Tel-Hashomer, and Sackler Faculty of Medicine (O.S., A.Z., R.D., N.R., S.G., A.I., A.M., U.M., A.L., D.V., U.S.), Tel-Hashomer; the Department of Statistics and Operations Research, Raymond and Beverly Sackler Faculty of Exact Sciences (D.M.S), Tel-Aviv University, Tel-Aviv; and the Anticoagulant Clinic, Maccabi Health Care Services, (S.B., U.S.), Tel-Aviv, Israel.
Abstract—The inherited thrombophilias—deficiencies of protein C, protein S, and antithrombin III—and the prothrombotic polymorphisms factor V G1691A and factor II G20210A predispose patients toward venous thromboembolism (VTE). The aim of this study was to determine the prevalence of single and combined prothrombotic factors in patients with idiopathic VTE and to estimate the associated risks. The study group consisted of 162 patients referred for work-up of thrombophilia after documented VTE. The controls were 336 consecutively admitted patients. In all subjects factor V G1691A, factor II G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T were analyzed by specific polymerase chain reactions and restriction enzymes. Activities of antithrombin III and protein C, free protein S antigen, and lupus anticoagulant were determined in a subset of 109 patients who were not receiving oral anticoagulants. The prevalences of heterozygotes and homozygotes for factor V G1691A and factor II G20210A among patients and controls were 40.1% versus 3.9% and 18.5% versus 5.4%, respectively (P=0.0001). The prevalence of homozygotes for MTHFR C677T in patients was 22.8% and in controls, 14.3% (P=0.025). Heterozygous and homozygous factor V G1691A, factor II G20210A, and homozygous MTHFR C677T were found to be independent risk factors for VTE, with odds ratios of 16.3, 3.6, and 2.1, respectively. Two or more polymorphisms were detected in 27 of 162 patients (16.7%) and in 3 of 336 controls (0.9%). Logistic regression analysis disclosed odds ratios of 58.6 (confidence interval [CI], 22.1 to 155.2) for joint occurrence of factor V and factor II polymorphisms, of 35.0 (CI, 14.5 to 84.7) for factor V and MTHFR polymorphisms, and of 7.7 (CI, 3.0 to 19.6) for factor II and MTHFR polymorphisms. Among 109 patients in whom a complete thrombophilic work-up was performed, 74% had at least 1 underlying defect. These data indicate that in most patients referred for evaluation of thrombophilia due to idiopathic VTE, 1 or more underlying genetic predispositions were discernible. The presence of >1 of the prothrombotic polymorphisms was associated with a substantial risk of VTE.
Key Words: thrombophilia • factor V G1691A (Leiden) • factor II G20210A • methylenetetrahydrofolate reductase • venous thromboembolism
This article has been cited by other articles:
 |
|
 |
|
  S. Kabukcu, N. Keskin, A. Keskin, and E. Atalay The Frequency of Factor V Leiden and Concomitance of Factor V Leiden With Prothrombin G20210A Mutation and Methylene Tetrahydrofolate Reductase C677T Gene Mutation in Healthy Population of Denizli, Aegean Region of Turkey Clinical and Applied Thrombosis/Hemostasis, April 1, 2007; 13(2): 166 - 171. [Abstract] [PDF]
|
|
|
|
 |
|
 B. R. Hairston, M. D. P. Davis, M. R. Pittelkow, and I. Ahmed Livedoid vasculopathy: further evidence for procoagulant pathogenesis. Arch Dermatol, November 1, 2006; 142(11): 1413 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bosler, J. Mattson, and D. Crisan Phenotypic Heterogeneity in Patients with Homozygous Prothrombin 20210AA Genotype: A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology J. Mol. Diagn., September 1, 2006; 8(4): 420 - 425. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Dentali, M. Crowther, and W. Ageno Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: a meta-analysis Blood, April 1, 2006; 107(7): 2766 - 2773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Pottier, G. Cormier, F. Truchaud, and B. Planchon Efficiency of Systematic Thrombophilia Screening in Idiopathic Venous Thrombosis: A Prospective Study in Internal Medicine Clinical and Applied Thrombosis/Hemostasis, July 1, 2005; 11(3): 243 - 251. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Tzoufi, S. Giotopoulou, P. Papadimitriou, E. Dokou, N. I. Kolaitis, A. Siamopoulou, and G. Vartholomatos Genetic Risk Factors Associated With Thrombosis in Children With Congenital Neurologic Disorders J Child Neurol, June 1, 2005; 20(6): 509 - 512. [Abstract] [PDF]
|
|
|
|
|
|
M. Tzoufi, S. Giotopoulou, P. Papadimitriou, E. Dokou, N. I. Kolaitis, A. Siamopoulou, and G. Vartholomatos Genetic Risk Factors Associated With Thrombosis in Children With Congenital Neurologic Disorders J Child Neurol, June 1, 2005; 20(6): 509 - 512. [Abstract] [PDF]
|
|
|
|
|
|
R. Duran, B. Biner, M. Demir, C. Celtik, and S. Karasalihoglu Factor V Leiden Mutation and Other Thrombophilia Markers in Childhood Ischemic Stroke Clinical and Applied Thrombosis/Hemostasis, January 1, 2005; 11(1): 83 - 88. [Abstract] [PDF]
|
|
|
|
 |
|
 M Leiba, U Seligsohn, Y Sidi, D Harats, B A Sela, J H Griffin, A Livneh, N Rosenberg, I Gelernter, H Gur, et al. Thrombophilic factors are not the leading cause of thrombosis in Behcet's disease Ann Rheum Dis, November 1, 2004; 63(11): 1445 - 1449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Glueck, N. Goldenberg, P. Wang, and D. Aregawi Ramifications of Four Concurrent Thrombophilic Mutations and One Hypofibrinolytic Mutation Clinical and Applied Thrombosis/Hemostasis, October 1, 2004; 10(4): 365 - 371. [Abstract] [PDF]
|
|
|
|
 |
|
 J. A. Caprini, C. J. Glase, C. B. Anderson, and K. Hathaway Laboratory Markers in the Diagnosis of Venous Thromboembolism Circulation, March 30, 2004; 109(12_suppl_1): I-4 - I-8. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Juul, A. Tybjaerg-Hansen, P. Schnohr, and B. G. Nordestgaard Factor V Leiden and the Risk for Venous Thromboembolism in the Adult Danish Population Ann Intern Med, March 2, 2004; 140(5): 330 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Inamoto, T. Katsuya, Y. Kokubo, T. Mannami, T. Asai, S. Baba, J. Ogata, H. Tomoike, and T. Ogihara Association of Methylenetetrahydrofolate Reductase Gene Polymorphism With Carotid Atherosclerosis Depending on Smoking Status in a Japanese General Population Stroke, July 1, 2003; 34(7): 1628 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Crowther and J. G. Kelton Congenital Thrombophilic States Associated with Venous Thrombosis: A Qualitative Overview and Proposed Classification System Ann Intern Med, January 21, 2003; 138(2): 128 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Carp, O. Salomon, D. Seidman, R. Dardik, N. Rosenberg, and A. Inbal Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss Hum. Reprod., June 1, 2002; 17(6): 1633 - 1637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Herrington, E. Vittinghoff, T. D. Howard, D. A. Major, J. Owen, D. M. Reboussin, D. Bowden, V. Bittner, J. A. Simon, D. Grady, et al. Factor V Leiden, Hormone Replacement Therapy, and Risk of Venous Thromboembolic Events in Women With Coronary Disease Arterioscler. Thromb. Vasc. Biol., June 1, 2002; 22(6): 1012 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Madonna, V. de Stefano, A. Coppola, F. Cirillo, A. M. Cerbone, G. Orefice, and G. Di Minno Hyperhomocysteinemia and Other Inherited Prothrombotic Conditions in Young Adults With a History of Ischemic Stroke Stroke, January 1, 2002; 33(1): 51 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.Y. Streifler, N. Rosenberg, A. Chetrit, R. Eskaraev, B.A. Sela, R. Dardik, A. Zivelin, B. Ravid, J. Davidson, U. Seligsohn, et al. Cerebrovascular Events in Patients With Significant Stenosis of the Carotid Artery Are Associated With Hyperhomocysteinemia and Platelet Antigen-1 (Leu33Pro) Polymorphism Stroke, December 1, 2001; 32(12): 2753 - 2758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Thomas Hypercoagulability Syndromes Arch Intern Med, November 12, 2001; 161(20): 2433 - 2439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Seligsohn and A. Lubetsky Genetic Susceptibility to Venous Thrombosis N. Engl. J. Med., April 19, 2001; 344(16): 1222 - 1231. [Full Text] [PDF]
|
|
|
|
|
|
U. Nowak-Gottl, R. Junker, W. Kreuz, A. von Eckardstein, A. Kosch, N. Nohe, R. Schobess, and S. Ehrenforth Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors Blood, February 15, 2001; 97(4): 858 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T C F Sykes, C Fegan, and D Mosquera Thrombophilia, polymorphisms, and vascular disease Mol. Pathol., December 1, 2000; 53(6): 300 - 306. [Abstract] [Full Text]
|
|
|
|
|
|
M. von Depka, U. Nowak-Gottl, R. Eisert, C. Dieterich, M. Barthels, I. Scharrer, A. Ganser, and S. Ehrenforth Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism Blood, November 15, 2000; 96(10): 3364 - 3368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M Ueland, H. Refsum, S. A. Beresford, and S. E. Vollset The controversy over homocysteine and cardiovascular risk Am. J. Clinical Nutrition, August 1, 2000; 72(2): 324 - 332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. K. Giri, T. Yamazaki, N. Sala, B. Dahlback, and P. G. de Frutos Deficient APC-cofactor activity of protein S Heerlen in degradation of factor Va Leiden: a possible mechanism of synergism between thrombophilic risk factors Blood, July 15, 2000; 96(2): 523 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kenet, S. Sadetzki, H. Murad, U. Martinowitz, N. Rosenberg, S. Gitel, G. Rechavi, and A. Inbal Factor V Leiden and Antiphospholipid Antibodies Are Significant Risk Factors for Ischemic Stroke in Children Stroke, June 1, 2000; 31(6): 1283 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Smirnov, O. Safa, N. L. Esmon, and C. T. Esmon Inhibition of Activated Protein C Anticoagulant Activity by Prothrombin Blood, December 1, 1999; 94(11): 3839 - 3846. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Shpilberg, I. Rabi, K. Schiller, R. Walden, D. Harats, K.S. Tyrrell, B. Coller, and U. Seligsohn Patients With Glanzmann Thrombasthenia Lacking Platelet Glycoprotein {alpha}IIb{beta}3 (GPIIb/IIIa) and {alpha}v{beta}3 Receptors Are Not Protected From Atherosclerosis Circulation, March 5, 2002; 105(9): 1044 - 1048. [Abstract] [Full Text] [PDF]
|
|